The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Tumor-induced perturbations of cytokines and immune cell networks
Open accessAbstract
Until recently, the intrinsically high level of cross-talk between immune cells, the complexity of immune cell development, and the pleiotropic nature of cytokine signaling have hampered progress in understanding the mechanisms of immunosuppression by which tumor cells circumvent native and adaptive immune responses. One technology that has helped to shed light on this complex signaling network is the cytokine antibody array, which facilitates simultaneous screening of dozens to hundreds of secreted signal proteins in complex biological samples. The combined applications of traditional methods of molecular and cell biology with the high-content, high-throughput screening capabilities of cytokine antibody arrays and other multiplexed immunoassays have revealed a complex mechanism that involves multiple cytokine signals contributed not just by tumor cells but by stromal cells and a wide spectrum of immune cell types. This review will summarize the interactions among cancerous and immune cell types, as well as the key cytokine signals that are required for tumors to survive immunoediting in a dormant state or to grow and spread by escaping it. Additionally, it will present examples of how probing secreted cell-cell signal networks in the tumor microenvironment (TME) with cytokine screens have contributed to our current understanding of these processes and discuss the implications of this understanding to antitumor therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“An investigation from NatureMedicine in 2007 reported thatmuch of the effectiveness of conventional treatments, such as chemotherapy and radiotherapy, may be due to innate and adaptive antitumor responses in humans and mice via toll-like receptor 4 signaling in dendritic cells, presumably in response to the release of…”
BackgroundCloning of a new cytokine that induces IFN-γ production by T cells
Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) · Nature · doi:10.1038/378088a0 · Cited by 2,600
Paradoxical roles of the immune system during cancer development
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1782 · Cited by 2,256
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,880
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360
Functional significance of the perforin/granzyme cell death pathway
Trapani, J. A., & Smyth, M. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri911 · Cited by 1,291
Vascular Endothelial Growth Factor
Ferrara, N. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179663 · Cited by 1,283
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
Molecular Antagonism and Plasticity of Regulatory and Inflammatory T Cell Programs
Yang, X. O., Nurieva, R., Martinez, G. J., Kang, H. S., Chung, Y., Pappu, B. P., Shah, B., Chang, S. H., Schluns, K. S., Watowich, S. S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.007 · Cited by 1,136
Rosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Immune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., & Fridman, W.-H. (2010) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,087
Pathways of apoptotic and non-apoptotic death in tumour cells
Okada, H., & Mak, T. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1412 · Cited by 1,044
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
IL-6 switches the differentiation of monocytes from dendritic cells to macrophages
Chomarat, P., Banchereau, J., Davoust, J., & Karolina Palucka, A. (2000) · Nature Immunology · doi:10.1038/82763 · Cited by 906
Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast
Scheel, C., Eaton, E. N., Li, S. H.-J., Chaffer, C. L., Reinhardt, F., Kah, K.-J., Bell, G., Guo, W., Rubin, J., Richardson, A. L., et al. (2011) · Cell · doi:10.1016/j.cell.2011.04.029 · Cited by 858
Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
TGF- β signaling in cancer – a double-edged sword
Akhurst, R. J., & Derynck, R. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02130-4 · Cited by 756
The SCID Mouse Mutant: Definition, Characterization, and Potential Uses
Bosma, M. J., & Carroll, A. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001543 · Cited by 748
Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720
Multiplexed protein measurement: technologies and applications of protein and antibody arrays
Kingsmore, S. F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2006 · Cited by 715
DeNardo, D. G., & Coussens, L. M. (2007) · Breast Cancer Research · doi:10.1186/bcr1746 · Cited by 677
The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts
Peinado, H., Lavotshkin, S., & Lyden, D. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.01.002 · Cited by 654
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Zheng, S. G., Wang, J., Wang, P., Gray, J. D., & Horwitz, D. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2018 · Cited by 597
Epidemiology of Stomach Cancer
Brenner, H., Rothenbacher, D., & Arndt, V. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-492-0_23 · Cited by 596
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
Atkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 583
Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A., & Middleton, G. W. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 575
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C., & Pienta, K. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042671 · Cited by 569
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053007 · Cited by 566
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9223-6 · Cited by 515
Decreased tumor surveillance in perforin-deficient mice.
van den Broek, M. E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1781 · Cited by 512
Prognostic significance of autoimmunity during treatment of melanoma with interferon
Krauze, M. T., Tarhini, A., Gogas, H., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507
Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P., & Kalinski, P. (2011) · Blood · doi:10.1182/blood-2011-07-365825 · Cited by 497
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C., Pardoll, D., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.018 · Cited by 474
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
Pan, P.-Y., Ma, G., Weber, K. J., Ozao-Choy, J., Wang, G., Yin, B., Divino, C. M., & Chen, S.-H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1882 · Cited by 467
Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.361 · Cited by 465
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Tumor-Driven Evolution of Immunosuppressive Networks during Malignant Progression
Kim, R., Emi, M., Tanabe, K., & Arihiro, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4128 · Cited by 445
Liao, D., Luo, Y., Markowitz, D., Xiang, R., & Reisfeld, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007965 · Cited by 437
Ma, J., Liu, L., Che, G., Yu, N., Dai, F., & You, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-112 · Cited by 437
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Decreased antigen presentation by dendritic cells in patients with breast cancer.
Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., & Carbone, D. P. (1997) · PubMed · Cited by 429
(1996) · Nature Medicine · doi:10.1038/nm1196-1267 · Cited by 429
Developmental plasticity of Th17 and Treg cells
Lee, Y. K., Mukasa, R., Hatton, R. D., & Weaver, C. T. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.021 · Cited by 423
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
Jamieson, T., Clarke, M., Steele, C. W., Samuel, M. S., Neumann, J., Jung, A., Huels, D., Olson, M. F., Das, S., Nibbs, R. J. B., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61067 · Cited by 391
The dynamic roles of TGF‐β in cancer
Meulmeester, E., & ten Dijke, P. (2011) · The Journal of Pathology · doi:10.1002/path.2785 · Cited by 388
IL-15/IL-15 receptor biology: A guided tour through an expanding universe
BUDAGIAN, V, BULANOVA, E., PAUS, R., & BULFONEPAUS, S. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.05.001 · Cited by 385
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
Yan, H. H., Pickup, M., Pang, Y., Gorska, A. E., Li, Z., Chytil, A., Geng, Y., Gray, J. W., Moses, H. L., & Yang, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0706 · Cited by 372
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
Interleukin-15 biology and its therapeutic implications in cancer
Steel, J. C., Waldmann, T. A., & Morris, J. C. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.09.004 · Cited by 361
Mast cells: the JEKYLL and HYDE of tumor growth
Theoharides, T. C., & Conti, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.02.013 · Cited by 351
At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 348
Ono, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00853.x · Cited by 342
Smad4 signalling in T cells is required for suppression of gastrointestinal cancer
Kim, B.-G., Li, C., Qiao, W., Mamura, M., Kasperczak, B., Anver, M., Wolfraim, L., Hong, S., Mushinski, E., Potter, M., et al. (2006) · Nature · doi:10.1038/nature04846 · Cited by 322
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment
Sato, Y., Goto, Y., Narita, N., & Hoon, D. S. B. (2009) · Cancer Microenvironment · doi:10.1007/s12307-009-0022-y · Cited by 319
Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment
Celis, J. E., Gromov, P., Cabezón, T., Moreira, J. M. A., Ambartsumian, N., Sandelin, K., Rank, F., & Gromova, I. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400009-mcp200 · Cited by 305
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
Dumitru, C. A., Lang, S., & Brandau, S. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.005 · Cited by 303
Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators
Angelo, L. S., & Kurzrock, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2416 · Cited by 295
Talmadge, J. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0182 · Cited by 285
The role of natural killer cells in immune surveillance of cancer
Whiteside, T. L., & Herberman, R. B. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80080-8 · Cited by 280
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Watkins, S. K., Egilmez, N. K., Suttles, J., & Stout, R. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1357 · Cited by 273
Fibroblasts as architects of cancer pathogenesis
Marsh, T., Pietras, K., & McAllister, S. S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.10.013 · Cited by 264
Lymphocytes in cancer development: Polarization towards pro-tumor immunity
Ruffell, B., DeNardo, D. G., Affara, N. I., & Coussens, L. M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.002 · Cited by 253
Nam, J.-S., Terabe, M., Kang, M.-J., Chae, H., Voong, N., Yang, Y.-A., Laurence, A., Michalowska, A., Mamura, M., Lonning, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0206 · Cited by 251
Sakamoto, K., Maeda, S., Hikiba, Y., Nakagawa, H., Hayakawa, Y., Shibata, W., Yanai, A., Ogura, K., & Omata, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1383 · Cited by 242
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.22009 · Cited by 235
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function.
Sharma, S. P., Stolina, M., Yang, S.-C., Baratelli, F. E., Lin, J. F.-H., Atianzar, K., Luo, J., Zhu, L., Lin, Y., Huang, M., et al. (2003) · PubMed · Cited by 232
Osaki, T., Péron, J., Cai, Q., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T., & Tahara, H. (1998) · PubMed · Cited by 231
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224
Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer
Kohrt, H. E., Nouri, N., Nowels, K., Johnson, D., Holmes, S., & Lee, P. P. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020284 · Cited by 220
MCP-1 mediates TGF-β–induced angiogenesis by stimulating vascular smooth muscle cell migration
Ma, J., Wang, Q., Fei, T., Han, J.-D. J., & Chen, Y.-G. (2007) · Blood · doi:10.1182/blood-2006-07-036400 · Cited by 213
Mier, J. W., Vachino, G., van der Meer, J. W. M., Numerof, R. P., Adams, S., Cannon, J. G., Bernheim, H. A., Atkins, M. B., Parkinson, D. R., & Dinarello, C. A. (1988) · Journal of Clinical Immunology · doi:10.1007/bf00916947 · Cited by 212
Prostaglandin E2 and Dexamethasone Inhibit IL-12 Receptor Expression and IL-12 Responsiveness
Wu, C.-Y., Wang, K., McDyer, J. F., & Seder, R. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2723 · Cited by 207
Inflammation and breast cancer
Constantinou, C., & Fentiman, I. S. (2013) · Breast Cancer Management · doi:10.2217/bmt.13.26 · Cited by 196
IFN-γ-Inducing Factor/IL-18 Administration Mediates IFN-γ- and IL-12-Independent Antitumor Effects
Osaki, T., Péron, J.-M., Cai, Q., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T., & Tahara, H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.4.1742 · Cited by 194
Chemotherapy and radiotherapy: Cryptic anticancer vaccines
Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., et al. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.001 · Cited by 193
On the cytokines produced by human neutrophils in tumors
Tecchio, C., Scapini, P., Pizzolo, G., & Cassatella, M. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.004 · Cited by 188
Th17 cells in cancer: help or hindrance?
Wilke, C. M., Kryczek, I., Wei, S., Zhao, E., Wu, K., Wang, G., & Zou, W. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr019 · Cited by 180
Issues in Using Progression-Free Survival When Evaluating Oncology Products
Fleming, T. R., Rothmann, M. D., & Lu, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4107 · Cited by 176
IFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene Expression
Dunn, G. P., Sheehan, K. C. F., Old, L. J., & Schreiber, R. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4316 · Cited by 173
Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer
Nesslinger, N. J., Sahota, R. A., Stone, B., Johnson, K., Chima, N., King, C., Rasmussen, D., Bishop, D., Rennie, P. S., Gleave, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1772 · Cited by 168
The paradox of tumor-associated neutrophils: Fueling tumor growth with cytotoxic substances
Houghton, A. M. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11297 · Cited by 166
Yang, A. S., & Lattime, E. C. (2003) · PubMed · Cited by 165
How are TH1 and TH2 effector cells made?
Amsen, D., Spilianakis, C. G., & Flavell, R. A. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.010 · Cited by 161
Wong, J. L., Berk, E., Edwards, R. P., & Kaliński, P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4366 · Cited by 157
Th memory for interleukin‐17 expression is stable in vivo
Lexberg, M. H., Taubner, A., Förster, A., Albrecht, I., Richter, A., Kamradt, T., Radbruch, A., & Chang, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838541 · Cited by 155
Protein microarrays and novel detection platforms
Chandra, H., Reddy, P. J., & Srivastava, S. (2011) · Expert Review of Proteomics · doi:10.1586/epr.10.99 · Cited by 149
The secretome in cancer progression
Paltridge, J. L., Belle, L., & Khew‐Goodall, Y. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.03.014 · Cited by 147
Gnerlich, J. L., Mitchem, J. B., Weir, J. S., Sankpal, N. V., Kashiwagi, H., Belt, B. A., Porembka, M. R., Herndon, J. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902609 · Cited by 139
The expression and role of CXC chemokines in colorectal cancer
Verbeke, H., Struyf, S., Laureys, G., & Damme, J. V. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.09.002 · Cited by 139
Torroella‐Kouri, M., Silvera, R., Rodríguez, D., Caso, R., Shatry, A. M., Opiela, S. J., Ilkovitch, D., Schwendener, R. A., Iragavarapu‐Charyulu, V., Cardentey, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3427 · Cited by 134
Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment
Ito, K., Stannard, K. A., Gabutero, E., Clark, A. M., Neo, S., Onturk, S., Blanchard, H., & Ralph, S. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9388-2 · Cited by 132
Bierie, B., Stover, D. G., Abel, T. W., Chytil, A., Gorska, A. E., Aakre, M. E., Forrester, E., Yang, H. H., Wagner, K., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5597 · Cited by 128
Ascierto, P. A., Capone, M., Urba, W. J., Bifulco, C. B., Botti, G., Lugli, A., Marincola, F. M., Ciliberto, G., Galon, J., & Fox, B. A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-54 · Cited by 124
Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression
Vidal‐Vanaclocha, F., Mendoza, L., Tellería, N., Salado, C., Valcárcel, M., Gallot, N., Carrascal, T., Egilegor, E., Beaskoetxea, J., & Dinarello, C. A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9013-3 · Cited by 122
Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B., Yagita∥, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3379 · Cited by 117
Son, Y. I., Dallal, R. M., Mailliard, R. B., Egawa, S., Jonak, Z., & Lotze, M. T. (2001) · PubMed · Cited by 109
Dendritic cell infiltration and prognosis of human hepatocellular carcinoma
Cai, X., Gao, Q., Qiu, S., Ye, S., Wu, Z.-Q., Fan, J., & Tang, Z. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0075-y · Cited by 100
Kesselring, R., Thiel, A., Pries, R., Trenkle, T., & Wollenberg, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605891 · Cited by 98
Hao, Q., Wang, L., & Tang, H. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00504.2008 · Cited by 87
Blockade of TGF‐β enhances tumor vaccine efficacy mediated by CD8+ T cells
Takaku, S., Terabe, M., Ambrosino, E., Peng, J., Lonning, S. M., McPherson, J. M., & Berzofsky, J. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24961 · Cited by 83
A model for cancer-suppressive inflammation
Haabeth, O. A. W., Bogen, B., & Corthay, A. (2012) · OncoImmunology · doi:10.4161/onci.21542 · Cited by 75
CTLA-4 blockade and the renaissance of cancer immunotherapy
D, S. M. M., & Nitti, D. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.05.003 · Cited by 72
CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer
Coventry, B. J., & Morton, J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601114 · Cited by 67
NSAIDs Modulate Clonal Evolution in Barrett's Esophagus
Kostadinov, R. L., Kuhner, M. K., Li, X., Sanchez, C. A., Galipeau, P. C., Paulson, T. G., Sather, C. L., Srivastava, A., Odze, R. D., Blount, P. L., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003553 · Cited by 66
Miyagawa, S., Soeda, J., Takagi, S., Miwa, S., Ichikawa, E., & Noike, T. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.07.018 · Cited by 60
Mattei, F., Schiavoni, G., Sestili, P., Spadaro, F., Fragale, A., Sistigu, A., Lucarini, V., Spada, M., Sanchez, M., Scala, S., et al. (2012) · Neoplasia · doi:10.1593/neo.121444 · Cited by 59
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
Alagkiozidis, I., Facciabene, A., Tsiatas, M. L., Carpenito, C., Benencia, F., Adams, S. F., Jonak, Z., June, C. H., Powell, D. J., & Coukos, G. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-77 · Cited by 57
The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer
Slaney, C. Y., Rautela, J., & Parker, B. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1642 · Cited by 54
Starnes, C. O. (1992) · Nature · doi:10.1038/360023b0 · Cited by 53
Izhak, L., Wildbaum, G., Jung, S., Stein, A., Shaked, Y., & Karin, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028305 · Cited by 52
Towards discovery‐driven translational research in breast cancer
Celis, J. E., Moreira, J. M. A., Gromova, I., Cabezón, T., Ralfkiær, U., Guldberg, P., Straten, P. T., Mouridsen, H. T., Friis, E., Holm, D. K., et al. (2004) · FEBS Journal · doi:10.1111/j.1432-1033.2004.04418.x · Cited by 51
Möller, B. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg146 · Cited by 45
An array of possibilities in cancer research using cytokine antibody arrays
Huang, R. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.2.299 · Cited by 33
Self-citationPickrell, B. B., Bhadkamkar, M. A., & Hollier, L. H. (2014) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000000688 · Cited by 32
Neoplastic “Black Ops”: Cancer's subversive tactics in overcoming host defenses
Biragyn, A., & Longo, D. L. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.005 · Cited by 31
Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer
Gill, S., Berry, S. R., Biagi, J., Butts, C., Buyse, M. E., Chen, E., Jonker, D., Marginean, C. E., Samson, B., Stewart, J., et al. (2011) · Current Oncology · doi:10.3747/co.v18is2.941 · Cited by 31
Sänchez‐Carbayo, M. (2010) · Tumor Biology · doi:10.1007/s13277-009-0014-z · Cited by 28
Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer
Gill, S., Berry, S. R., Biagi, J. J., Butts, C. A., Buyse, M. E., Chen, E., Jonker, D. J., Maginean, C., Samson, B., Stewart, J., et al. (2011) · Current Oncology · doi:10.3747/co.v18i0.958 · Cited by 25
Proteomic strategies and challenges in tumor metastasis research
Hudler, P., Goršič, M., & Komel, R. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9339-7 · Cited by 24
Preexisting antitumor immunity augments the antitumor effects of chemotherapy
Zhang, L., Feng, D., Yu, L. X., Tsung, K., & Norton, J. A. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1417-7 · Cited by 21
(2009) · Springer eBooks · doi:10.1007/978-0-387-78665-0_6441 · Cited by 17
Cited by
Choo, Y. W., Kang, M., Kim, H. Y., Han, J., Kang, S., Lee, J.-R., Jeong, G.-J., Kwon, S. P., Song, S. Y., Go, S., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b02446 · Cited by 465
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Driver and Passenger Mutations in Cancer
Pon, J. R., & Marra, M. A. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040312 · Cited by 355
Role of nonresolving inflammation in hepatocellular carcinoma development and progression
Yu, L.-X., Ling, Y., & Wang, H.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 301
Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Mirlekar, B. (2022) · SAGE Open Medicine · doi:10.1177/20503121211069012 · Cited by 258
Metadata
- Authors
- Burkholder, B., Huang, R.-Y., Burgess, R., Luo, S., Jones, V. S., Zhang, W., Lv, Z.-Q., Gao, C.-Y., Wang, B.-L., Zhang, Y.-M., & Huang, R.-P.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 1845
- Issue
- 2
- Pages
- 182-201
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2002308570
- Cited by
- 356
- References
- 161
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.